Neovacs S.A FCF yield
¿Qué es el FCF yield de Neovacs S.A?
El FCF yield de Neovacs S.A. es -4.57%
¿Cuál es la definición de FCF yield?
Free cash flow yield (FCF yield) is a financial ratio that compares the free cash flow per share to the market value per share. The ratio is calculated by dividing free cash flow per share by the current share price.
ttm (trailing twelve months)
Free cash flow yield is a good measure of the company’s cash flow in respect to the company’s size. Larger companies tend to have a higher cash flow yield, but it’s not always the case. The higher the free cash flow yield, the more cash the company is generating that can be quickly accessed to satisfy its obligations. The lower the free cash flow yield, the more money investors are putting into the company with little result. The higher the ratio, the more attractive the investment is as it suggests that investors are paying less for each unit of free cash flow.
Free cash flow acts as an indicator of how capable a company is of repaying all of its obligations. It is a solid indicator of how financially stable a company is. It is calculated as:
Free cash flow yield = Free cash flow per share / market price per share
FCF yield de compañías en Sector Health Care en EURONEXT en comparadas con Neovacs S.A
¿Qué hace Neovacs S.A?
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Empresas con fcf yield similar a Neovacs S.A
- Potbelly Corp tiene FCF yield de -4.61%
- Seachange International tiene FCF yield de -4.60%
- Gunpoint Exploration tiene FCF yield de -4.59%
- Elcora Advanced Materials tiene FCF yield de -4.59%
- Strategic Trust tiene FCF yield de -4.58%
- Brookfield Property Partners L.P tiene FCF yield de -4.57%
- Neovacs S.A tiene FCF yield de -4.57%
- GAN tiene FCF yield de -4.56%
- Khoon tiene FCF yield de -4.56%
- Enstar tiene FCF yield de -4.56%
- Neovasc Inc tiene FCF yield de -4.56%
- Blackbird plc tiene FCF yield de -4.56%
- Tianjin Jiuri New Materials Co tiene FCF yield de -4.55%